PRAMEF33

Across TCGA pan-cancer cohorts, PRAMEF33 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRAMEF33 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRAMEF33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF33 expression acts as an unfavorable survival marker.

HNSC, LUAD, and THCA are the cancer types where PRAMEF33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.158	0.686	<.001	42	view →
LUAD	OS	Median	All	0.057	0.788	<.001	18	view →
THCA	OS	Median	All	0.323	0.955	<.001	8	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
SKCM	OS	Median	All	0.670	0.789	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRAMEF33–HNSC (OS)

Open the HNSC breakdown →